Table 1.
Patient and disease related characteristics in patients receiving VRD and VCD induction therapy before autologous transplant for newly diagnosed multiple myeloma
| Variable | VRD(N=914; 80.5%) Median (range) or N (%) |
VCD (N=221;19.5%) Median (range) or N (%) |
P-value |
|---|---|---|---|
|
| |||
| Age, years | 60 (30 – 82) | 61 (32 – 79) | 0.06 |
|
| |||
| Sex, Male | 503 (55) | 119 (54) | 0.75 |
|
| |||
| Self-reported race | 0.004 | ||
| Caucasian | 576 (63) | 162 (73) | |
| African-American | 278 (30) | 41 (19) | |
| Other/Missing | 60 (6) | 18 (8) | |
|
| |||
| Karnofsky performance score, ≥90% | 470 (51) | 131 (59) | 0.09 |
|
| |||
| Renal adjusted HCT-CI Score # | 0.74 | ||
| 0 | 279 (31) | 77 (35) | |
| 1 | 136 (15) | 35 (16) | |
| 2+ | 498 (55) | 109 (49) | |
|
| |||
| International Staging System (ISS) | <0.001 | ||
| I | 296 (32) | 49 (22) | |
| II | 309 (34) | 52 (24) | |
| III | 158 (17) | 76 (34) | |
| Missing | 151 (17) | 44(20) | |
|
| |||
| Cytogenetics | 337 (37) | 78 (35) | 0.89 |
| High-risk [t(4;14), t(14;16), t(14;20), del17p, +1q, HR2] | |||
| Standard risk, including normal | 544 (60) | 134 (61) | |
| Missing/not done | 33 (4) | 9 (4) | |
|
| |||
| Myeloma subtype | 0.07 | ||
| IgG | 515 (56) | 106 (48) | |
| IgA | 210 (23) | 52 (24) | |
| Light chain myeloma | 172 (19) | 60 (27) | |
| Non-secretory/other | 17 (2) | 3 (1) | |
|
| |||
| eGFR at diagnosis, <60 mL/min/1.73m2: ## | 241 (26) | 105 (48) | <0.001 |
|
| |||
| Serum creatinine at diagnosis, ≥ 2 mg/dl | 74 (8) | 64 (29) | <0.001 |
|
| |||
| eGFR prior to HCT, < 60 mL/min/1.73m2 ## | 78 (9) | 67 (30) | <0.001 |
|
| |||
| Serum creatinine prior to transplant, ≥ 2 mg/dl | 14 (2) | 26 (12) | <0.001 |
|
| |||
| Pre-transplant response | 0.21 | ||
| CR | 152 (17) | 38 (17) | |
| VGPR | 438 (48) | 92 (42) | |
| PR | 324 (35) | 91 (41) | |
|
| |||
| Pre-transplant response, ≥ VGPR | 590 (65) | 130 (59) | 0.11 |
Table Abbreviations: CR: complete response, eGFR: estimated glomerular filtration rate, PR: partial response, VCD: bortezomib, cyclophosphamide and dexamethasone, VGPR: very good partial response, VRD: bortezomib, lenalidomide and dexamethasone.
#
Renal HCT-CI score missing in one patient in the VRD group.
##
eGFR at diagnosis missing in 59 patients (6%) in VRD group and 18 (8%) in VCD group. eGFR prior to HCT missing in 1 patient in VRD group (0%) and 3 patients in VCD group. Therefore numbers do not add to 100%.